FDA halts Vir, GSK antibody use in response to COVID subvariant's spread

U.S. authorities on Tuesday withdrew their authorization of Vir Biotechnology and GlaxoSmithKline's COVID-19 antibody treatment after a subvariant of omicron became dominant in the country.